Incidental Adrenal Nodule in a Patient with Prior Breast Cancer
A 58-year-old woman with a history of stage II breast cancer treated with mastectomy and adjuvant chemotherapy 4 years ago undergoes a staging CT of the chest, abdomen, and pelvis for new back pain. The scan shows no recurrent disease but reveals a 2.4 cm left adrenal nodule with a homogeneous appearance and unenhanced attenuation of 8 HU. She is asymptomatic, normotensive, and takes no antihypertensives. Her most recent oncologic imaging 14 months ago did not report an adrenal nodule. The referring oncologist asks whether this needs biopsy or PET before the next treatment cycle. The radiologist must decide on the next step and document it clearly in the report.
1. How should the 8 HU unenhanced attenuation be interpreted, and what imaging follow-up (if any) is appropriate?
Read the worked answer
An unenhanced attenuation ≤10 HU is essentially diagnostic of a lipid-rich adenoma, with reported specificity near 98% when using a threshold of 10 HU. A homogeneous 2.4 cm nodule at 8 HU in a normotensive asymptomatic patient is benign and requires no further imaging or biopsy. The key reasoning is that the attenuation value itself resolves the question; the patient's cancer history does not override a benign imaging phenotype. The report should state the benign characterization explicitly so the oncologist does not order unnecessary PET or biopsy. Note that a 14-month interval since prior imaging is not a reason to escalate-interval growth is only meaningful when the baseline characterization is indeterminate.
2. Suppose the nodule had measured 35 HU on the unenhanced phase. What would your algorithm be, and how does the patient's oncology history change management?
Read the worked answer
At 35 HU the nodule is indeterminate (lipid-poor). The next step is a dedicated adrenal protocol: unenhanced, portal venous (~60–70 s), and delayed (~15 min) imaging with absolute and relative washout calculation. Absolute washout >60% or relative washout >40% indicates adenoma and ends the workup. If washout is insufficient, the differential includes metastasis, pheochromocytoma, and other neoplasms. With a known breast cancer history, a metastasis is plausible; PET/CT or biopsy may then be considered, but only after biochemical exclusion of pheochromocytoma (plasma free metanephrines) if biopsy is contemplated. The reasoning hinges on the fact that the oncology history raises the pretest probability of metastasis but does not bypass the washout algorithm, which remains the most specific noninvasive discriminator.
3. What reporting and communication obligations apply if the radiologist judges the nodule benign?
Read the worked answer
The radiologist should (1) explicitly characterize the nodule as a benign lipid-rich adenoma in the impression, (2) recommend no further imaging, and (3) avoid ambiguous language such as 'cannot exclude metastasis' that would trigger reflexive workup. Routine direct communication to the referring clinician is not mandated for a definitively benign finding, but clear documentation prevents downstream overtesting. This reflects the noninterpretive skill of stewardship: matching recommendation intensity to diagnostic certainty and communicating it unambiguously.